Anzeige
Mehr »
Login
Freitag, 01.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
200.000 Unzen pro Jahr: Die Goldaktie, die kurz davor steht, Geschichte zu schreiben
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
205 Leser
Artikel bewerten:
(1)

Helio Space Corporation: Helio Corporation Announces Launch of Radar Antennas on NASA Europa Clipper Mission

BERKELEY, CA / ACCESSWIRE / October 29, 2024 / Heliospace, a subsidiary of Helio Corporation (OTC Pink:HLEO) has announced the successful launch of its deployable radar antennas aboard the NASA Europa Clipper spacecraft on Oct 14, 2024. Heliospace designed, assembled, tested, and delivered these antennas under contract with Caltech as part of the Radar for Europa Assessment and Sounding: Ocean to Near-surface (REASON) instrument onboard Europa Clipper.

Heliospace

Heliospace
Heliospace

The Heliospace radar antennas are an extremely compact design accommodated on the edges of the Europa Clipper spacecraft solar arrays and will deploy to form two large dipole antennas up to 17.6 m in length, along with four smaller dipoles during the flight. Heliospace co-founder and CEO Greg Delory, a former space scientist, expressed his excitement about this event: "All of us at Heliospace are pleased to have been able to use our company's technology to help advance NASA's mission to explore Jupiter's moon Europa. This is one of the solar system's most fascinating objects, where conditions for life may exist, and to be able to contribute to its exploration is an exciting moment for us."

Under principal investigator Dr. Donald Blankenship of the University of Texas, Austin, REASON is a dual-frequency ice penetrating radar instrument designed to characterize and sound Europa's icy crust from the near-surface to the ocean, revealing the hidden structure of Europa's ice shell and potential water within. The Europa Clipper program is managed by the NASA Jet Propulsion Laboratory.

About Helio Corporation:

Helio Corporation is a technology, engineering and research and development (R&D) holding company serving commercial, government and non-profit organizations. Our wholly owned subsidiary, Heliospace Corporation ("Heliospace"), is an aerospace company specializing in the design, engineering, assembly and test of space flight qualified hardware and provides systems engineering, modeling, analysis, integration and test services to customers in government, commercial, private and non-profit markets. With deep expertise in civil space missions combined with a growing business serving commercial companies, our primary company objective is to enable humanity's pursuit of the scientific and commercial development of space. https://helio.space

Note Regarding Forward Looking Statements:

Some of the matters discussed herein may contain forward-looking statements that involve significant risk and uncertainties. Forward-looking statements can be identified by the use of words like "believes," "could," "possibly," "probably," "anticipates," "estimates," "projects," "expects," "may," "will," "should," "seek," "intend," "plan," "expect," or "consider" or the negative of these expressions or other variations, or by discussions of strategy that involve risks and uncertainties. All forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual transactions, results, performance or achievements to be materially different from any future transactions, results, performance or achievements expressed or implied by such forward-looking statements. We base these forward-looking statements on current expectations and projections about future events and the information currently available to us. Although we believe that the assumptions for these forward-looking statements are reasonable, any of the assumptions could prove to be inaccurate. Consequently, no representation or warranty can be given that the estimates, opinions, or assumptions made in or referenced by this presentation will prove to be accurate. We caution you that the forward-looking statements in this presentation are only estimates and predictions, or statements or current intent. Actual results or outcomes, or actions that we ultimately undertake, could differ materially from those anticipated in the forward-looking statements due to risks, uncertainties or actual events differing from the assumptions underlying these statements. We caution investors not to rely on the forward-looking statements contained in, or made in connection with this presentation. The Company undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or changes in the Company's business plans or model.

Contact Information

Kelsey Rex
Marketing Manager, MarketLeverage
kelsey@marketleverage.com
510-545-2666

SOURCE: Helio Corporation

.

View the original press release on newswire.com.

© 2024 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.